DE60239815D1 - Codon-optimisierte HIV-RT-nef-Gag DNA Impfstoffe - Google Patents

Codon-optimisierte HIV-RT-nef-Gag DNA Impfstoffe

Info

Publication number
DE60239815D1
DE60239815D1 DE60239815T DE60239815T DE60239815D1 DE 60239815 D1 DE60239815 D1 DE 60239815D1 DE 60239815 T DE60239815 T DE 60239815T DE 60239815 T DE60239815 T DE 60239815T DE 60239815 D1 DE60239815 D1 DE 60239815D1
Authority
DE
Germany
Prior art keywords
nef
codon
fragment
dna vaccines
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239815T
Other languages
English (en)
Inventor
Andrew Beaton
Peter Franz Ertl
Gerald Wayne Gough
Andrew Lear
John Philip Tite
Wely Catherine Ann Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority claimed from PCT/EP2002/010592 external-priority patent/WO2003025003A2/en
Application granted granted Critical
Publication of DE60239815D1 publication Critical patent/DE60239815D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60239815T 2001-09-20 2002-09-18 Codon-optimisierte HIV-RT-nef-Gag DNA Impfstoffe Expired - Lifetime DE60239815D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines
PCT/EP2002/010592 WO2003025003A2 (en) 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines

Publications (1)

Publication Number Publication Date
DE60239815D1 true DE60239815D1 (de) 2011-06-01

Family

ID=43927344

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239815T Expired - Lifetime DE60239815D1 (de) 2001-09-20 2002-09-18 Codon-optimisierte HIV-RT-nef-Gag DNA Impfstoffe

Country Status (7)

Country Link
KR (1) KR101067231B1 (de)
AT (1) ATE506439T1 (de)
DE (1) DE60239815D1 (de)
HK (1) HK1066830A1 (de)
MY (1) MY131949A (de)
TW (1) TWI329647B (de)
ZA (1) ZA200402189B (de)

Also Published As

Publication number Publication date
MY131949A (en) 2007-09-28
HK1066830A1 (en) 2005-04-01
KR20040039387A (ko) 2004-05-10
ATE506439T1 (de) 2011-05-15
TWI329647B (en) 2010-09-01
ZA200402189B (en) 2005-07-27
KR101067231B1 (ko) 2011-09-22

Similar Documents

Publication Publication Date Title
WO2003025003A3 (en) Hiv-gag codon-optimised dna vaccines
MY145614A (en) Vaccine
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
DE60325892D1 (de) Stellungs- und verwendungsverfahren
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
DE69941049D1 (de) Retrovirales verabreichungssystem
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
DK0640133T3 (da) Rekombinante DNA-molekyler, der koder for aminopeptidaseenzymer og deres anvendelse i fremstillingen af vacciner mod helmin
ATE420183T1 (de) Antigen-konstrukte, für den nachweis und die unterscheidung von antikörpern gegen hiv
TW200502245A (en) Vaccine
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
DE60239815D1 (de) Codon-optimisierte HIV-RT-nef-Gag DNA Impfstoffe
DK1066328T3 (da) Kimært protein, der indeholder en intramolekylær chaperon-lignende sekvens, og dets anvendelse til insulinproduktion
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2003089571A3 (en) Ehrlichia canis genes and vaccines
DK1379273T3 (da) Nukleinsyreadjuvanser
HUP0300297A2 (en) Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
DE60221805D1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
WO2003052122A3 (en) Gp41 inhibitor
WO2002022663A3 (en) Stress resistant retroviruses
DE60313743D1 (de) Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen
HUP0500099A2 (hu) Glükuronil C5-epimeráz, az azt kódoló DNS és ezek alkalmazása
ATE414905T1 (de) Diabetesmodell
WO2001007625A3 (en) Ehrlichia canis genes and vaccines